Lucas H P Bernts1, Myrte K Neijenhuis1, Marie E Edwards2, Jeff A Sloan3, Jenna Fischer4, Rory L Smoot4, David M Nagorney4, Joost P H Drenth1, Marie C Hogan5. 1. Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, the Netherlands. 2. Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, MN. 3. Quality of Life Group, Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 4. Department of Surgery, Mayo Clinic, Rochester, MN. 5. Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, MN. Electronic address: hogan.marie@mayo.edu.
Abstract
BACKGROUND: Polycystic liver disease can cause severe symptomatic hepatomegaly. Combined partial hepatectomy and cyst fenestration can be performed to reduce liver volume and symptom burden. We aimed to assess change in symptom relief and quality of life 6 months after partial hepatectomy and cyst fenestration in polycystic liver disease patients. METHOD: We established a prospective cohort between 2014 and 2018 at a referral center in the United States. Patients who underwent partial hepatectomy and cyst fenestration for volume-related symptoms were included. Primary outcome was change in polycystic liver disease-related symptoms, measured with Polycystic Liver Disease Questionnaire. Secondary outcomes were change in liver volume (computed tomography/ magnetic resonance imaging) and change in quality of life, measured with the 12-Item Short Form Survey and the EuroQoL Visual Analogue Scale. Questionnaire scores range from 0 to 100 and were assessed before and 6 months after partial hepatectomy and cyst fenestration. Surgical complications were scored according to Clavien-Dindo (grade 1 to 5). RESULTS: We included 18 patients (mean age 52 years, 82% female). Partial hepatectomy and cyst fenestration reduced median liver volume (4,917 to 2,120 mL). Symptoms, measured with Polycystic Liver Disease Questionnaire, decreased (76.9 to 34.8 points; P < .001) 6 months after surgery; 15/16 symptoms declined after treatment, with the most impact seen on early satiety and dyspnea. Quality of life also improved after surgery: median physical and mental component scales of the 12-Item Short Form Survey and EuroQoL Visual Analog Scale increased (24.9 to 45.7, P = .004; 40.5 to 55.4, P = .02; and 40.0 to 72.5, P = .003). Major complications (grade 4) occurred in 2 patients. There was no procedure-related mortality. CONCLUSION: Partial hepatectomy and cyst fenestration substantially improves symptom burden and quality of life in highly symptomatic polycystic liver disease patients.
BACKGROUND:Polycystic liver disease can cause severe symptomatic hepatomegaly. Combined partial hepatectomy and cyst fenestration can be performed to reduce liver volume and symptom burden. We aimed to assess change in symptom relief and quality of life 6 months after partial hepatectomy and cyst fenestration in polycystic liver diseasepatients. METHOD: We established a prospective cohort between 2014 and 2018 at a referral center in the United States. Patients who underwent partial hepatectomy and cyst fenestration for volume-related symptoms were included. Primary outcome was change in polycystic liver disease-related symptoms, measured with Polycystic Liver Disease Questionnaire. Secondary outcomes were change in liver volume (computed tomography/ magnetic resonance imaging) and change in quality of life, measured with the 12-Item Short Form Survey and the EuroQoL Visual Analogue Scale. Questionnaire scores range from 0 to 100 and were assessed before and 6 months after partial hepatectomy and cyst fenestration. Surgical complications were scored according to Clavien-Dindo (grade 1 to 5). RESULTS: We included 18 patients (mean age 52 years, 82% female). Partial hepatectomy and cyst fenestration reduced median liver volume (4,917 to 2,120 mL). Symptoms, measured with Polycystic Liver Disease Questionnaire, decreased (76.9 to 34.8 points; P < .001) 6 months after surgery; 15/16 symptoms declined after treatment, with the most impact seen on early satiety and dyspnea. Quality of life also improved after surgery: median physical and mental component scales of the 12-Item Short Form Survey and EuroQoL Visual Analog Scale increased (24.9 to 45.7, P = .004; 40.5 to 55.4, P = .02; and 40.0 to 72.5, P = .003). Major complications (grade 4) occurred in 2 patients. There was no procedure-related mortality. CONCLUSION: Partial hepatectomy and cyst fenestration substantially improves symptom burden and quality of life in highly symptomatic polycystic liver diseasepatients.
Authors: Loes van Keimpema; Frederik Nevens; René Adam; Robert J Porte; Panagiotis Fikatas; Thomas Becker; Preben Kirkegaard; Herold J Metselaar; Joost P H Drenth Journal: Transpl Int Date: 2011-09-29 Impact factor: 3.782
Authors: Gabriele I Kirchner; Kinan Rifai; Tobias Cantz; Bjoern Nashan; Christoph Terkamp; Thomas Becker; Christian Strassburg; Hannelore Barg-Hock; Siegfried Wagner; Rainer Lück; Juergen Klempnauer; Michael P Manns Journal: Liver Transpl Date: 2006-08 Impact factor: 5.799
Authors: Lucas H P Bernts; Sebastiaan G Echternach; Wietske Kievit; Camiel Rosman; Joost P H Drenth Journal: Surg Endosc Date: 2018-10-17 Impact factor: 4.584
Authors: Renée Duijzer; Thijs R M Barten; Christian B Staring; Joost P H Drenth; Tom J G Gevers Journal: J Clin Gastroenterol Date: 2022-08-19 Impact factor: 3.174